BioCentury
ARTICLE | Clinical News

FDA approves Nicox’s Zerviate for ocular itching

June 2, 2017 7:19 PM UTC

Nicox S.A. (Euronext:COX) said FDA approved an NDA for Zerviate cetirizine (AC-170) to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's first in the U.S.

Last October, FDA issued a complete response letter for Zerviate, citing a GMP inspection at a third party facility. The company resubmitted an NDA on March 8 (see BioCentury, Oct. 17, 2016 & March 13, 2017)...

BCIQ Company Profiles

Nicox S.A.

BCIQ Target Profiles

Histamine H1 receptor (HRH1)